{"id":"W4221013240","doi":"10.1158/1538-7445.sabcs21-pd13-05","title":"Abstract PD13-05: Alpelisib + fulvestrant in patients with <i>PIK3CA</i>-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Oncology; Clinical endpoint; Breast cancer; Cancer; Metastatic breast cancer; Palbociclib; Clinical trial; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001750277,0.0007526345,0.001321852,0.0003146236,0.0002943893,0.001392717,0.0006522873,0.0006840091,0.004558342],"category_scores_gemma":[0.001044115,0.0003200168,0.001765141,0.000450151,0.0005571279,0.0007591376,0.000437358,0.002161704,0.0007357803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001559084,"about_ca_system_score_gemma":0.00192927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00196716,"about_ca_topic_score_gemma":0.004567842,"domain_scores_codex":[0.999357,0.0002874021,0.00003297466,0.0001446721,0.00008655908,0.00009129992],"domain_scores_gemma":[0.9991215,0.0001247328,0.0002051718,0.00007593589,0.0001081094,0.0003644836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8268255,0.01000924,0.04424256,0.0004538727,0.002921212,0.00009569077,0.0001095848,0.001495012,0.01339532,0.0002779912,0.008720499,0.09145348],"study_design_scores_gemma":[0.4903254,0.2770142,0.2000944,0.0001931354,0.004619917,0.0005177087,0.0001943835,0.004106328,0.009392478,0.0007572711,0.01267698,0.0001078614],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989184,0.001879393,0.0003952632,0.0004570684,0.00006441076,0.0007431193,0.004801328,0.0000712602,0.002404179],"genre_scores_gemma":[0.9834516,0.000818641,0.0008944194,0.0007381994,0.00008395508,0.0006220746,0.01158211,0.00002394966,0.001785101],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004558342,"threshold_uncertainty_score":0.01524919,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06264451628072079,"score_gpt":0.4018803996710633,"score_spread":0.3392358833903425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}